| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Viracta Therapeutics, Inc. (VIRX) has 0 insiders with recent SEC Form 4 filings, including 2 buys and 9 sells. VIRX is classified in the Biotechnology industry within the Health Care sector.
| Role | Insider | Shares | Value | 30d |
|---|
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| Feb 27, 2024 | Chevallard Daniel R. | CFO And COO | Sale+OE | 3,405 | $0.73 | $2,493.14 | -3.2% | |
| Dec 1, 2023 | Rothera Mark | President And CEO | Buy | 100,000 | $0.49 | $49,361.68 | +192.0% | |
| Nov 28, 2023 | Chevallard Daniel R. | CFO And COO | Sale+OE | 3,720 | $0.50 | $1,860.00 | -3.6% | |
| Aug 28, 2023 | Chevallard Daniel R. | CFO And COO | Sale+OE | 3,512 | $1.45 | $5,092.40 | -3.5% | |
| May 25, 2023 | Chevallard Daniel R. | CFO And COO | Sale+OE | 3,635 | $1.42 | $5,160.25 | -3.8% | |
| Feb 27, 2023 | Rojkjaer Lisa | Chief Medical Officer | Sale+OE | 2,156 | $1.68 | $3,624.67 | -4.3% | |
| Feb 27, 2023 | Chevallard Daniel R. | CFO And COO | Sale+OE | 3,599 | $1.68 | $6,050.64 | -3.9% | |
| Nov 28, 2022 | Chevallard Daniel R. | CFO And COO | Sale+OE | 3,532 | $2.72 | $9,605.63 | -4.0% | |
| Nov 28, 2022 | Rojkjaer Lisa | Chief Medical Officer | Sale+OE | 2,116 | $2.72 | $5,754.04 | -4.4% | |
| Aug 26, 2022 | Rojkjaer Lisa | Chief Medical Officer | Sale+OE | 2,190 | $4.01 | $8,785.84 | -4.7% |